Pharmaceutical News and Articles

Monthly Cabotegravir-Rilpivirine Injections Superior to Standard Oral ART for HIV With Adherence Challenges

Monthly injections of long-acting cabotegravir-rilpivirine are superior to standard oral antiretroviral therapy (ART) in persons with human immunodeficiency vir

Muscular Strength Associated With Lower Mortality in Older Women

Greater muscular strength is associated with lower mortality for older women, according to a study published online Feb. 13 in JAMA Network Open.Michael J. LaMo

Stable, Supportive Shoes No Aid for Hip Osteoarthritis

Stable, supportive shoes are not superior to flat, flexible shoes for improving hip osteoarthritis pain while walking, according to a study published online Feb

FDA Approves Desmoda (desmopressin acetate) Oral Solution for Central Diabetes Insipidus

Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026

Merck (NYSE MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three pivotal Phase 3 trials evaluating

ViiV Healthcare Reports Positive 12-Month Data Showing Investigational bNAb Lotivibart (N6LS) Maintains High Levels of Viral Suppression in Long-Acting HIV Treatment Regimen

London, 25 February 2026 ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced pos

Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy

Gilead Sciences, Inc. (Nasdaq GILD) today announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing a treatment switch

Early Study Results from Johnson & Johnson Show Promising Antitumor Activity with Combination of Pasritamig and Docetaxel in Advanced Prostate Cancer

RARITAN, N.J., February 26, 2026 Johnson Johnson (NYSE JNJ) today announced preliminary results from a Phase 1b study evaluating pasritamig (JNJ-78278343), a fi

FDA Approves Hernexeos, the First Targeted Therapy for Adults with HER2-Mutant Advanced NSCLC as an Initial Treatment Option

FDA Approves Dupixent for Allergic Fungal Rhinosinusitis

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic f